ImmuCell Corporation (NASDAQ:ICCC) Short Interest Update

ImmuCell Corporation (NASDAQ:ICCC) was the target of a significant increase in short interest in March. As of March 13th, there was short interest totaling 27,331 shares, an increase of 71.6% from the February 26th total of 15,924 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily volume of 13,770 shares, the short-interest ratio is presently 2.0 days.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded ImmuCell from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, February 24th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, ImmuCell has an average rating of “Hold”.

ImmuCell Trading Down 0.2%

NASDAQ ICCC traded down $0.01 on Friday, reaching $6.52. 9,481 shares of the company were exchanged, compared to its average volume of 13,419. The business’s fifty day moving average price is $6.40 and its 200 day moving average price is $6.12. The stock has a market capitalization of $58.98 million, a P/E ratio of -59.27 and a beta of 0.27. The company has a current ratio of 4.21, a quick ratio of 1.76 and a debt-to-equity ratio of 0.27. ImmuCell has a fifty-two week low of $4.52 and a fifty-two week high of $7.60.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Steadtrust LLC acquired a new stake in ImmuCell during the third quarter worth about $198,000. Mesirow Financial Investment Management Inc. boosted its holdings in ImmuCell by 199.6% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after purchasing an additional 24,303 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of ImmuCell by 4.2% in the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after buying an additional 2,907 shares during the period. Institutional investors and hedge funds own 13.47% of the company’s stock.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.